TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: IRIS-BVS AMI Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 19 and more~* Acute myocardial infarction~* Intervention with Bioresorbable Vascular Scaffold~* Agreed with written informed consent form~Exclusion Criteria:~* Bypass graft surgery (CABG) recommended~* Lesion with previous bypass graft surgery (CABG)~* Severe calcification and/or severe tortuosity~* Contraindication to antiplatelet agent or Inability to take dual antiplatelet therapy within 1 year~* Life expectancy of 1year and under~* Subjects scheduled to receive cardiac surgery or serious non-cardiac surgery~* Cardiac shock

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acute myocardial infarction (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Asthma & COPD Guideline Implementation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Primary care physicians were eligible if they: 1) managed at least 15 patients with asthma and 15 patients with COPD per month in an office setting; and 2) agreed to designate an appropriately trained person at his/her site to identify eligible study patients, collect consent, and provide a questionnaire to patients.~Patients were eligible if they: 1) spoke French or English; and 2) had a diagnosis of asthma or COPD (as per their participating PCP). Furthermore, patients with asthma had to be between 18 and 45 years of age, and patients with COPD had to be between 40 and 75 years of age and have a smoking history of \>10 pack-years.~Exclusion Criteria:~Physicians were excluded if they: 1) had presented at a continuing medical education (CME) event on asthma or COPD in last year; 2) had completed any specialty training in respiratory diseases; or 3) practiced primarily at walk-in clinics, with children, or in emergency departments.~Patients were excluded if they: 1) had any condition which could interfere with study measurements (as per their participating PCP); 2) had any known respiratory disorders other than asthma or COPD; or 3) were currently participating in another clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard practice group (SPG) (Type: ACTIVE_COMPARATOR): Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
- Targeted Intervention Strategy (TISG) (Type: ACTIVE_COMPARATOR): interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals older than 18 years who score a 12 or greater on the Reflux Disease Questionnaire and have failed a four week trial of daily proton pump inhibitor.~2. Subjects without gastroesophageal reflux disease (GERD) undergoing upper endomicroscopy for other indications will be recruited into study as controls.~Exclusion Criteria:~1. Barrett's esophagus~2. Use of twice daily proton pump inhibitor within 4 weeks of study entry~3. Esophageal varices~4. Coagulopathy (aspirin, NSAIDS and Plavix are allowed. Coumadin, Xarelto, heparin are not allowed.)~5. Gastrointestinal cancer or mass~6. Previous surgery involving the esophagus, stomach or duodenum~7. Pregnancy~8. Allergy to either sucralfate or proton pump inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Proton Pump Inhibitor (PPI) Therapy (Type: OTHER): 2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
- Sucralfate (Type: OTHER): 4x daily Sucralfate slurry, 1g, for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of any age undergoing SCT.~Exclusion Criteria:~* Prior proton or photon radiation treatment for cancer of the oral cavity, head or neck; cranial boost in patients receiving total body irradiation; known history of allergy to xylitol; inability to use a mouth rinse or dental wipes.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xylitol wipes (Type: EXPERIMENTAL): None
- Placebo wipes (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men with prostate cancer (with or without metastatic disease) on ADT for at least 2 months~2. Age less than 65 years~3. Body Mass Index (BMI) less than 32~4. Willingness to undergo image guided intervention~5. Greater than 28 hot flashes per week.~Exclusion Criteria:~1. Conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; metastatic disease in or near the cervical spine; goiter;cardiac/pulmonary compromise; sleep apnea; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye)~2. Current treatment of prostate cancer with radium or chemotherapy~3. Use of treatments in the past two months that can affect HF (e.g., testosterone or androgen supplementation) Note: SSRIs, serotonin norepinephrine uptake inhibitors, and membrane stabilizers will be allowed but must be on stable unchanged dose for at least 8 weeks)~4. Inability to write, speak, or read in English

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- .5% Bupivacaine (Type: EXPERIMENTAL): Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with recent PPROM between 31 weeks + 6 days and 35 weeks + 6 days (estimated gestational age based on an ultrasound examination before 18 weeks of gestation), not in labour 24 hours after admission\*, will be considered eligible for the study provided the following inclusion criteria (\*For patients transferred from a remote level 2 centre to one of the participating sites within the first hours after PPROM, the onset of the 24-hour screening period will be the time of admission in the centre of origin. Patients in Group A will be given their first dose of antenatal steroids before the transfer)~* Single and otherwise uncomplicated pregnancy~* Recent history (less than 48 hours) of leaking with the two followings within 24 hours after primary medical assessment: Documentation of fluid from the vagina and Positive Fern test, or positive Nitrazine test, or Positive ACTIM PROM test~* Antenatal steroids course initiated after the rupture for women with PPROM between 31 + 6 and 33 + 6 weeks~* Normal fetal heart rate trace using an external ultrasound transducer~* Written informed consent obtained before inclusion and randomization~Exclusion Criteria:~* Multiple pregnancy~* HIV positive mother~* Active HSV cervical lesions~* Major fetal anomaly on ultrasound examination performed after admission~* Intrauterine growth restriction estimated on ultrasound below the 5th percentile or preeclampsia~* Placenta abruption present at the time of the diagnosis of PPROM or occurring within the first 24 hours after rupture~* Clinical chorioamnionitis existing before or at the time of the diagnosis of PPROM or developing within the first 24 hours after rupture~* Non-reassuring fetal testing present at the time of the diagnosis of PPROM or occurring within the first 24 hours after the rupture. It implies that expected criteria for standard fetal assessment parameters have not been met, including the Non-Stress test and the Biophysical profile Score. This will be diagnosed at the discretion of the attending physician.~* More generally, any maternal or fetal reason for an immediate delivery, either existing at admission or occurring within the 24 hours after admission.~* Mother refusal or inability to provide consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Expectant management
- 2 (Type: ACTIVE_COMPARATOR): Induction of delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed neuroendocrine tumor metastatic to the liver~  * Well-differentiated or moderately well-differentiated neuroendocrine tumors~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral CT scan~* Symptomatic disease, meeting one of the following criteria:~  * Refractory carcinoid symptoms, defined as Carcinoid Symptom Severity scale \> 2 despite use of octreotide acetate at ≥ 200 mcg subcutaneously three times daily (or 20 mg intramuscularly once monthly) for ≥ 4 weeks~ * Evidence of radiographic progression with either of the following manifestations:~    * Moderate-severe right upper quadrant pain and unintentional weight loss \> 10%~   * Decline in Karnofsky performance status \> 10 points~* At least a 20% increase in the sum of the longest diameters of target lesions in the liver within the past 12 months~* No more than 75% replacement of normal liver by neuroendocrine tumor~* No more than 20% arteriovenous lung shunting on a technetium Tc 99m macro-aggregated albumin nuclear scan~* No equivocal, nonmeasurable, or nonevaluable liver metastasis~PATIENT CHARACTERISTICS:~* Karnofsky performance status 50-100%~* Life expectancy ≥ 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine ≤ 1.5 mg/dL~* Bilirubin ≤ 2.0 mg/dL~* Albumin ≥ 3.0 g/dL~* Absolute granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 65,000/mm³~* Hemoglobin \> 9.0 g/dL~* INR ≤ 1.4~* No hepatic arterial anatomy that would preclude the administration of study treatment into the liver~* No nonmalignant disease that would preclude study participation~* No other malignancy within the past 5 years except for cured basal cell carcinoma of the skin or cured carcinoma in situ of the uterine cervix~PRIOR CONCURRENT THERAPY:~* Prior surgery, chemotherapy, or locally ablative technique for the liver cancer allowed~* No prior radiotherapy to the upper abdomen that includes the liver in the treatment field~* No investigational drug or agent/procedure (i.e., participation in another clinical trial) within the past 4 weeks~* No other specific anticancer treatment (other than octreotide acetate) during and for 3 months after completion of study therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sir-Spheres (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Objectives of Women With Gestational Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age between 15 and 32 weeks since last menstrual date,~* received education on gestational diabetes mellitus,~* able to read and understand French.~Exclusion Criteria:~* known type 1 or type 2 diabetes,~* treatment interfering woth glucose metabolism,~* deficit may hinder the understanding of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal glycemic control (Type: ACTIVE_COMPARATOR): GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
- Low glycemic control (Type: EXPERIMENTAL): GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTSD diagnosis~Exclusion Criteria:~* Pregnancy~* Traumatic Brain Injury greater than mild~* Primary sleep disorder~* Caffeinism~* Active substance use disorder~* Active suicidal risk~* Antipsychotic medication, antibiotics, sedatives, some antihypertensive or antiarrhythmic medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Iloperidone / Placebo (Type: EXPERIMENTAL): During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
- Placebo / Iloperidone (Type: EXPERIMENTAL): During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ga-68-DOTATOC -PET in the Management of Pituitary Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Naïve, unoperated pituitary tumour with GH or ACTH or TSH production or NFPA without treatment with somatostatin analogues or dopamine agonists.~Exclusion Criteria:~* Patient who may not attend to the protocol according to the investigators opinion.~* Pregnancy or lactating~* Isolated prolactin producing tumours~* Overproduction of gonadotrophins~* Carcinoids ie ectopic CRF production~* Known or suspected allergy to the trial product or related products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68 DOTATOC PET in pituitary adenomas (Type: EXPERIMENTAL): To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \> 18 years of age~* Evidence of hypercapnia (PCO2 ≥ 45mmHg) secondary to COPD-OSA overlap, OHS, Neuromuscular disease / weakness~* Requiring NIV / NIPPV outpatient~* Ability to operate a smart device / tablet~* Informed consent~Exclusion Criteria:~* Non-English or Non-Spanish- speaking (device videos and surveys are available in English or Spanish only)~* Patients unable to give consent~* Pregnant women~* Prisoners~* Patients \<18 years of age~* Patient already on NIPPV/ CPAP at home and compliant on therapy~* Significant non-pulmonary conditions (CHF with EF \< 40%), Pulmonary hypertension with PASP\> 60 mmGH, severe valvular heart disease, end-stage renal disease or end-stage liver disease.~* Patients without health insurance~* Residing out of state (Pennsylvania)~* Patients with current or history of drug / narcotic dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vivify + EMS (Type: ACTIVE_COMPARATOR): This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
- Vivify Only (Type: ACTIVE_COMPARATOR): This group will receive the telemedicine tablet and kit, with the same protocol as defined above.~No EMS home visits will be set up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Firmagon (Degarelix) Intermittent Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed adenocarcinoma of the prostate for which intermittent endocrine treatment therapy is indicated~* PSA level meeting both of these criteria:~* PSA level of ≥ 5 ng/mL.~* For patients with recurrence after radiotherapy or cryotherapy: Patients should have a serum PSA (two measurements) to be \>2 ng/mL higher than a previously confirmed PSA nadir.~* screening serum testosterone level above the lower limit of normal range defined as \>2.2 ng/mL.~Exclusion Criteria:~* Has had previous or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation)~* Has received therapy with the 5-alpha reductase inhibitors finasteride or dutasteride within 12 weeks and 25 weeks, respectively, prior to screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 10 month degarelix therapy (Type: ACTIVE_COMPARATOR): None
- 4 month degarelix therapy arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy